skip to Main Content

Discovery of Pancreatic Neuroendocrine Subtypes Could Help Predict Likelihood of Recurrence

Discovery of Pancreatic Neuroendocrine Subtypes Could Help Predict Likelihood of Recurrence
Researchers have discovered two distinct subtypes of pancreatic neuroendocrine tumors – known as pNETs – that have dramatically different risks of recurrence following surgical treatment [or surgery]. The finding could yield predictive tests, ease anxiety in patients whose tumors are found to be unlikely to recur, while focusing vigilant follow-up monitoring on patients with pNETs having a higher rate of recurrence.

Until now, these pancreatic neuroendocrine tumors were viewed as relatively identical from a clinical point of view. While some pNETs never develop recurrent metastases following removal of the primary tumor, other patients experience recurrence within a few years, and there has been no specific way to predict these outcomes. Read more . . . 


Back To Top